James W. Brush, M.D.

Jamie is a General Partner and Portfolio Manager on the Frazier Life Sciences team and co-leads Frazier’s public equity investment strategy.

Jamie joined Frazier Life Sciences in 2016 and invests in private and public biotechnology companies. Jamie co-leads the Frazier Life Sciences public investment strategy and serves as a co-Portfolio Manager of the Frazier Life Sciences Public Fund (FLSPF) with Albert Cha. Jamie has led many of Frazier’s successful public investments and represented Frazier on the board of directors of Amunix Pharmaceuticals (sold to Sanofi) and Maze Therapeutics (NASDAQ: MAZE).

Prior to joining Frazier, Jamie was a management consultant with the Boston Consulting Group, where he was a core member of the Healthcare Practice. In this capacity, he led projects involving Biotechnology mergers and acquisitions, R&D, manufacturing, and business development strategy.

Jamie received his M.D. from the University of Southern California, where he was inducted into the Alpha Omega Alpha honors society, and his B.A. from Middlebury College. He completed his post-graduate training in Internal Medicine at Beth Israel Deaconess Medical Center in Boston.